Abbott Laboratories stock falls after fourth quarter revenue miss and lower profit guidance
Abbott Laboratories shares fell 7 percent after reporting fourth quarter revenue of 11.46 billion dollars and issuing a weak profit outlook for early 2026.
Insights:
Abbott Laboratories reported fourth-quarter 2025 revenue of $11.46 billion, failing to meet the $11.80 billion expected by Wall Street analysts. While the company's fourth-quarter adjusted earnings per share reached $1.50, which was in line with analyst expectations, the broader financial results led to a 7% decline in the company's stock price following the announcement.
The healthcare giant also issued cautious forward-looking guidance for the first quarter of 2026. Abbott Laboratoriesprojected adjusted per-share profit in the range of $1.12 to $1.18, a forecast that sits below the analyst consensus estimate of $1.20. All four of the company's business segments reported sales figures that were below expectations for the quarter.
